Listen in the Podli app 🎧
Follow your favourite podcasts, listen offline and in the car with CarPlay and Android Auto, and always pick up where you left off. Free to try.
Featuring an interview with Prof Andreas Hochhaus, including the following topics:
- Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00)
- Mechanistic differences among first-generation tyrosine kinase inhibitors (TKIs), second-generation TKIs and asciminib (6:09)
- Potential mechanisms of adverse events documented with TKIs (10:23)
- Recent survey of patients with CML regarding goals of therapy and clinical implications; considerations for discontinuation of therapy (16:23)
- Comparative tolerability of asciminib and other agents used to manage CML; promoting adherence to treatment plans for patients (27:14)
- Comparative efficacy of asciminib and other agents used to treat CML (40:01)
- Potential areas for improvement in community oncology practice patterns; family planning in the context of CML treatment (43:53)
- Practical care strategies for CML patients; future developments (52:32)
CME information and select publications
